Benign prostatic enlargement assessment

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Benign growth around the prostatic urethra can narrow the outlet, while smooth-muscle tone adds a dynamic component to resistance. The same degree of enlargement produces different symptoms in different patients because prostate shape, bladder contraction and storage behaviour also matter. Assessment therefore asks three separate questions: what is bothering the patient, is the prostate likely to be responsible, and has the urinary tract already suffered consequences? An anatomical finding should not become a shortcut around these questions.

A man may attend because of sleep disturbance, fear of cancer, sexual concerns or a wish to avoid sudden retention while travelling. These priorities influence whether observation, medication or a procedure offers useful benefit. A validated symptom score provides a baseline, but a patient with a modest score and hydronephrosis needs a different plan from one with severe bother and normal emptying. Cancer can coexist with BPE; neither a benign-feeling gland nor improvement with treatment eliminates that possibility.

Key points

Benign prostatic hyperplasia is histological, enlargement is anatomical, and obstruction is a functional diagnosis.
A smooth enlarged prostate supports BPE but does not prove the cause of a weak stream.
Separate symptom burden from complication risk: painless chronic retention can threaten renal function despite little bother.
Discuss PSA testing when it can inform management, including cancer concerns and progression-directed treatment decisions.
Initial uncomplicated assessment uses history, examination, urinalysis and symptom measurement; specialist tests answer specific unresolved questions.
Consider a 5-alpha-reductase inhibitor for an enlarged gland with progression risk, rather than expecting immediate symptomatic relief.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Age and androgen signalling

Benign stromal and epithelial proliferation becomes more common with age and depends on androgen signalling within the prostate. The presence of growth does not specify the severity of symptoms.

Multifactorial susceptibility

Inherited susceptibility, metabolic factors and local inflammatory processes may contribute to prostatic growth. Clinical consequences also depend on anatomy, outlet tone and the bladder’s ability to respond.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Periurethral growth
Expansion around the prostatic urethra can narrow the outlet or distort the bladder neck. Intravesical protrusion can affect function without a directly proportional increase in total gland volume.
2
Dynamic resistance
Smooth muscle in the prostate and bladder neck contributes to outlet tone. Reducing this component can improve symptoms without removing the tissue responsible for anatomical enlargement.
3
Bladder adaptation
The detrusor must generate sufficient pressure to overcome outlet resistance. Storage changes and incomplete emptying may develop, but symptoms alone cannot establish which functional abnormality dominates.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Probable benign pattern

Progressive hesitancy, weak flow and prolonged voiding in an older man, with a smooth symmetrically enlarged prostate, are compatible with BPE. Urgency and nocturia may coexist. Establish the trajectory and medication history, including recent additions that could have precipitated deterioration.

Quantifying burden

Use IPSS alongside its quality-of-life question and the patient’s own goal. Scores of 1–7, 8–19 and 20–35 represent mild, moderate and severe symptom bands. Ask separately about leakage and sexual function because a score may not capture these important consequences fully.

Evidence of complication

Palpable bladder, overflow leakage, recurrent infection, stones or renal dysfunction change the management threshold. Ask specifically about new bedwetting and painless abdominal swelling. Longstanding large residuals can be missed if the patient is still able to pass small volumes.

Findings against simple BPE

A hard irregular prostate, visible haematuria, painful urination, perineal pain, previous instrumentation or neurological symptoms need separate consideration. In a younger patient or after pelvic surgery, benign age-related enlargement is a less satisfactory explanation for new voiding difficulty.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Urine dipstick and symptom-directed cultureFirst step
Why
Identify infection, haematuria, glycosuria or proteinuria that may alter the assessment.
Interpretation and limitations
A urinary infection can temporarily worsen symptoms and influence PSA interpretation. Blood requires its own evaluation; do not attribute it to prostatic vascularity without considering other causes. Culture is selected by clinical symptoms and the intended intervention.
02
PSA after informed discussion
Why
Support decisions about possible cancer and, when appropriate, estimate enlargement or progression risk.
Interpretation and limitations
Explain that PSA is prostate-specific rather than cancer-specific. An abnormal DRE or concerning clinical course warrants assessment irrespective of a reassuring numerical value. Record retention, infection and 5-alpha-reductase inhibitor use when interpreting results and deciding timing.
03
Renal function and upper tract ultrasound
Why
Identify obstructive consequences when the history or examination suggests renal risk.
Interpretation and limitations
Creatinine is not routinely required for every uncomplicated initial male LUTS presentation. Palpable bladder, enuresis and recurrent infection increase concern. In chronic retention exceeding one litre or with a palpable bladder, CG97 recommends creatinine and upper tract imaging.
04
Specialist flow, residual and prostate imaging
Why
Clarify emptying and obtain anatomical information when it will change treatment choice.
Interpretation and limitations
Interpret maximum flow with the voided volume and repeat an unrepresentative result. Residual urine can reflect obstruction or a weak detrusor. Ultrasound estimates gland volume and shape for drug or procedure selection; DRE is an imprecise volume measurement.
05
Selected cystoscopy or urodynamics
Why
Resolve a specific diagnostic uncertainty before an irreversible treatment decision.
Interpretation and limitations
Cystoscopy may identify a stricture, tumour or relevant median lobe. Pressure-flow studies can distinguish outlet resistance from poor contraction when the result would change management. Routine invasive testing in all otherwise uncomplicated men adds burden without equivalent benefit.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Prostate cancer

Cancer may coexist with enlargement or present with a suspicious DRE or PSA pattern. LUTS alone neither proves malignancy nor reliably distinguishes benign from malignant pathology.

Urethral stricture

Previous urethral injury, infection or instrumentation can produce a fixed narrowing and a poor stream. Enlarging the prostatic treatment plan will not address a more distal lesion.

Detrusor underactivity

A poorly contracting bladder may produce low flow, prolonged voiding and residual urine that resemble obstruction. Selected pressure-flow testing can clarify the mechanism before outlet surgery.

Overactive bladder or polyuria

Urgency and nocturia may mainly reflect storage dysfunction or excessive urine production. A diary and directed systemic assessment prevent every complaint being assigned to the prostate.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Low immediate riskObservation with an explicit baselineFirst stepSymptoms are tolerable and no renal or obstructive complication is identified.

1PreferredRecord symptom burden, examination, urine findings and the patient’s preferred outcome. Explain what enlargement can and cannot tell us about cancer or obstruction, and address the reason for the consultation.
2Agree practical changes to intake, evening habits and constipation where relevant. Keep a route back for worsening flow, infections, blood or inability to void rather than promising that benign symptoms cannot progress.
3At review compare the actual functional impact with baseline. Persistent bothersome symptoms may justify medication even without dangerous obstruction; patient preference is part of that decision.

02Progression riskChoose treatment matched to the glandBothersome symptoms coexist with convincing enlargement and risk of future progression.

1Discuss an alpha blocker when relief of moderate or severe symptoms is needed after conservative measures are insufficient or unsuitable. Assess blood pressure, falls and interacting drugs before prescribing.
2NICE supports a 5-alpha-reductase inhibitor when the prostate exceeds an estimated 30 g or PSA exceeds 1.4 ng/ml and progression risk is high. Establish appropriate cancer assessment rather than treating an unexplained PSA elevation as proof of benign growth.
3Consider combination treatment for bothersome moderate or severe symptoms with enlargement or the PSA criterion. Explain the delayed benefit and additional adverse effects, and arrange early symptom review plus later progression-treatment review.

03Complicated enlargementDrain and refer when organs are threatenedRetention is accompanied by hydronephrosis, renal impairment or repeated obstructive events.

1Arrange prompt urological assessment and bladder drainage when renal impairment or hydronephrosis is secondary to chronic retention. Record initial drainage and monitor subsequent output; symptom tablets do not remove this immediate risk.
2Investigate whether persistent upper tract dilation requires additional drainage or a different diagnosis. Treat infection and correct fluid or biochemical problems in parallel, involving renal specialists when recovery is incomplete.
3DefinitiveDiscuss definitive outlet treatment after stabilisation when appropriate. Consider bladder contractility and the patient’s fitness, because a technically successful outlet procedure cannot guarantee catheter independence.

Key medicines and prescribing safety2 treatments · regimens, roles and cautions

Symptomatic treatment for men with LUTS attributed to benign prostatic enlargement.

Tamsulosin prolonged-release capsule

400 micrograms orally once daily after breakfast or the first meal; swallow the capsule whole. Review at 4–6 weeks; continuation depends on benefit.

Avoid with a history of orthostatic hypotension or severe hepatic insufficiency. Use caution below creatinine clearance 10 ml/min. Starting this capsule before planned cataract or glaucoma surgery is not recommended; ensure the eye team knows about previous as well as current tamsulosin use.

Long-term reduction of enlargement and progression events in suitable men with BPE.

Finasteride tablet

5 mg orally once daily, with or without food; swallow whole. Allow at least six months to judge response and continue long term when beneficial.

No routine renal dose adjustment is required; hepatic impairment is insufficiently studied. Discuss sexual and psychiatric effects, prompt review for mood changes, PSA suppression and avoidance of broken-tablet handling during pregnancy.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Acute retention

A patient can abruptly lose the ability to void, sometimes after illness, constipation or a medicine change. The resulting painful distension needs prompt drainage and assessment of the precipitant.

Upper tract injury

Sustained high-pressure retention may cause hydronephrosis and renal dysfunction. Lack of pain or severe symptom scores does not protect against this potentially serious consequence.

Infection and calculi

Ineffective emptying can favour recurrent urinary infection and bladder stone formation. These complications strengthen the case for assessment of the outlet and a durable management strategy.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record a drug review at 4–6 weeks after starting an alpha blocker; ask about dizziness, falls, ejaculatory symptoms and improvement in the patient’s chosen activity.
Review progression-directed therapy at 3–6 months, then at 6–12-month intervals when stable. Reconcile adherence before deciding that delayed benefit represents failure.
Interpret PSA on treatment against the medication history: finasteride commonly suppresses it by about half, and sustained subsequent rises require assessment.
Recheck renal function, residual trends and upper tract findings in patients with known retention; reduction in symptom score alone does not establish organ recovery.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Shape can outweigh size

A gland projecting into the bladder or a tight bladder neck can interfere with emptying even when overall volume is not impressive. Procedure planning needs anatomical detail beyond a finger estimate.

Bother and danger

Some patients adapt their routine so successfully that symptoms appear mild. Ask about fluid avoidance, prolonged toilet visits and accidents before deciding that low reported bother reflects low disease burden.

Persistent storage symptoms

Improved flow after treatment may reveal that nocturia or urgency has another contributor. Revisit the diary and sleep or metabolic history rather than automatically escalating outlet treatment.

Shared procedural expectations

Ask about ejaculation and future fertility before surgery becomes urgent. The patient may accept a higher retreatment risk to preserve ejaculation, or prioritise the most durable relief instead.

11Common pitfallsFrequent interpretation and management errors.

01
Do not use an elevated PSA as an automatic reason to start finasteride without assessing whether cancer or a transient confounder needs attention.
02
A normal creatinine does not prove good emptying, and a raised creatinine may have causes beyond obstruction; interpret both within the whole assessment.
03
Do not present alpha blockade as reliably preventing long-term retention or surgery; symptom improvement and disease modification are different treatment effects.
04
Avoid assuming that prostate surgery will cure all nocturia, restore detrusor strength or preserve ejaculation; discuss realistic outcomes before consent.

Find your next topic